Marché mondial du diagnostic tissulaire – Tendances et prévisions de l’industrie jusqu’en 2031

Analyse et taille du marché du diagnostic tissulaire

Le marché du diagnostic tissulaire est porté par des avancées permettant une identification précise des maladies à partir des tissus organiques et tumoraux. Il est utilisé dans le diagnostic et l'évaluation de diverses maladies, notamment le cancer, les maladies infectieuses, les troubles auto-immuns et les maladies génétiques. En outre, les principaux acteurs de ce marché investissent dans la recherche et le développement pour innover dans les techniques de diagnostic, améliorant ainsi la compétitivité du marché. Par exemple, Roche Diagnostics a investi dans le développement de solutions avancées de diagnostic tissulaire, telles que le test VENTANA PD-L1 (SP142). Ce test permet de diagnostiquer certains types de cancer et de prédire la réponse à l'immunothérapie, ce qui stimule la croissance du marché.

Français La taille du marché mondial du diagnostic tissulaire était évaluée à 565,62 millions USD en 2023 et devrait atteindre 943,15 millions USD d'ici 2031, avec un TCAC de 6,6 % au cours de la période de prévision de 2024 à 2031. En plus des informations sur le marché telles que la valeur du marché, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe de recherche sur le marché de Data Bridge comprend une analyse approfondie des experts, une analyse des importations/exportations, une analyse des prix, une analyse de la consommation de production, une analyse des brevets et le comportement des consommateurs.  

Portée et segmentation du marché du diagnostic tissulaire  

Market Definition

Tissue diagnostics involves examining tiny samples of body tissues to identify diseases such as cancer. Doctors take tissue samples through biopsies or surgeries. These samples are then analyzed under a microscope to look for abnormal cells or structures. Tissue diagnostics helps doctors make accurate diagnoses and determine the best treatment options for patients.

Tissue Diagnostics Market Dynamics

Drivers

• Rising Demand for Diagnostic Testing Services  

With aging populations and changing lifestyles contributing to the growing disease burden, there is an urgent need for effective diagnostic solutions. This surge in demand, reflected in the expanding cancer market size, underscores the importance of early detection for successful treatment outcomes. Tissue diagnostics through techniques such as biopsies and molecular testing, plays a pivotal role in accurately identifying cancer types and guiding treatment decisions.

For instance,

• GRAIL has initiated non-invasive blood tests that analyze circulating tumor DNA, allowing for the detection of cancer at its earliest stages. This breakthrough technology showcases the critical role of tissue diagnostics in improving cancer detection rates and treatment outcomes

As a result, the market for tissue diagnostics continues to expand rapidly to meet the rising healthcare demands worldwide.

• Growing Demand for Personalized Medicine

The growing demand for personalized medicine is driven by advancements in molecular and genetic technologies, enabling tailored treatment strategies based on individual patient characteristics. This approach considers genetic makeup, lifestyle factors, and disease biomarkers to optimize treatment efficacy and minimize adverse effects. Patients increasingly seek personalized therapies that offer higher efficacy rates and fewer side effects compared to traditional treatments.

For instance,

• Foundation Medicine has created comprehensive genomic profiling tests that analyze tumor DNA to identify specific mutations and guide treatment decisions. This approach enables oncologists to prescribe personalized therapies tailored to the patient's unique genetic profile, leading to improved treatment outcomes and patient satisfaction

 In addition, healthcare providers recognize the potential cost savings and improved patient outcomes associated with personalized medicine, further fueling its adoption and driving market growth in the healthcare industry.

Opportunities

• Strategic Collaborations and Partnerships with Healthcare Providers

Pharmaceutical companies often collaborate with biotechnology firms or academic institutions to access novel technologies, drug candidates, or research insights. Similarly, diagnostic companies may form partnerships with healthcare providers or data analytics firms to enhance diagnostic accuracy and expand market reach.

For instance,

• AstraZeneca partnered with Merck & Co. to develop and commercialize Lynparza (olaparib) as a potential treatment for multiple cancer types. This collaboration combines AstraZeneca's expertise in oncology with Merck's global reach, accelerating drug development and expanding patient access to advanced cancer treatments

These collaborations facilitate the development of new therapies, diagnostic tools, and treatment approaches, ultimately benefiting patients by improving healthcare outcomes. Furthermore, strategic alliances enable companies to navigate regulatory challenges more effectively, accelerate product development timelines, and capitalize on emerging market opportunities, thereby driving growth and competitiveness in the tissue diagnostic sector.

• Increasing Geriatric Population Impacts Demand for Tissue Diagnostics

As individuals age, they become more susceptible to various diseases, including cancer and degenerative conditions. Tissue diagnostics play a crucial role in diagnosing these age-related illnesses, enabling early detection and personalized treatment strategies. With a growing number of elderly individuals requiring diagnostic services, the demand for tissue diagnostics rises accordingly. This demographic trend drives market growth in the tissue diagnostics sector, highlighting the importance of catering to the healthcare needs of aging populations.

Restraints/Challenges

• Infrastructure Limitations in Developing Regions

Infrastructure limitations in developing regions, such as inadequate laboratory facilities, unreliable electricity supply, and limited access to specialized equipment, hinder the effectiveness of tissue diagnostics. Without proper infrastructure, tissue samples may be mishandled or improperly stored, leading to inaccurate results Limited access to reliable electricity, clean water, and proper waste disposal facilities further hinders the implementation of tissue diagnostics technologies. As a result, healthcare providers struggle to offer timely and accurate diagnostic services, leading to delays in diagnosis, treatment, and disease management. Additionally, infrastructure constraints impede the penetration of tissue diagnostics solutions into these regions, limiting market growth opportunities and exacerbating healthcare disparities between developed and developing economies.

• Lack of Skilled Personnel for Analyzer Operation

Advanced diagnostic analyzers require specialized training and expertise to operate effectively, interpret results accurately, and troubleshoot technical issues. However, the shortage of skilled personnel hampers the adoption and utilization of these sophisticated technologies, leading to suboptimal performance and reduced efficiency in diagnostic laboratories. This constraint not only impedes the timely delivery of diagnostic services but also limits the market potential for tissue diagnostics solutions, as healthcare facilities may struggle to fully leverage the benefits of these innovative tools without adequately trained staff.

This tissue diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Global Tissue Diagnostics Market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In May 2022, Leica Biosystems (Nussloch, Germany) launched a compact, dual-retort tissue processor, the HistoCore PEGASUS Plus. Its compact design and dual-retort system enhance laboratory workflow, improving efficiency and throughout. This innovation drives the adoption of tissue processing technology, stimulating market expansion and innovation
• In March 2021, Roche launched DISCOVERY Green HRP chromogen detection kit to expand immunohistochemistry multiplexing in cancer research In March 2021, Roche launched DISCOVERY Green HRP chromogen detection kit to expand immunohistochemistry multiplexing in cancer research. This innovative kit enhances researchers' ability to detect multiple biomarkers simultaneously, advancing understanding and diagnosis of cancer, thereby driving demand for immunohistochemistry solutions and fostering market expansion

Tissue Diagnostics Market Scope

The tissue diagnostics market is segmented into four notable segments based on product, technology, disease, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Consumables
• Instruments

Technology

• Immunohistochemistry
• In Situ Hybridization
• Digital Pathology and Workflow Management
• Special Staining

Disease

• Breast Cancer
• Gastric Cancer
• Lymphoma
• Prostate Cancer
• Non-Small Cell Lung Cancer
• Other Diseases

End User

• Hospitals
• Pharmaceutical Companies
• Research Laboratories
• Diagnostic Centres
• Ambulatory Surgical Centres
• Others

Tissue Diagnostics Market Regional Analysis/Insights

The tissue diagnostics market is analysed and market size insights and trends are provided by based on product, technology, disease, and end user as referenced above.

The countries covered in the tissue diagnostics market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, rest of Europe, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.

North America dominates the tissue diagnostics market because of the rising prevalence of cancer in the region and growing investment in healthcare infrastructure. The presence of several public programs aims to minimize cancer incidences and raise the demand for cancer diagnosis in the regional market. The Cancer Prevention and Control Research Network is a flagship program by the Centers for Disease Control and Prevention that focuses on cancer prevention in this region.

Asia-Pacific is expected to be the fastest-growing region in the tissue diagnostic market due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.

La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces de Porter, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.   

Croissance de la base installée des infrastructures de santé et pénétration des nouvelles technologies

Le marché du diagnostic tissulaire vous fournit également une analyse détaillée du marché pour chaque pays, la croissance des dépenses de santé pour les équipements en capital, la base installée de différents types de produits pour le marché du diagnostic tissulaire, l'impact de la technologie utilisant des courbes de vie et les changements dans les scénarios réglementaires des soins de santé et leur impact sur le marché du diagnostic tissulaire. Les données sont disponibles pour la période historique 2016-2021.

Analyse du paysage concurrentiel et des parts de marché du diagnostic tissulaire

Le paysage concurrentiel du marché du diagnostic tissulaire fournit des détails par concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liées au marché du diagnostic tissulaire.

Certains des principaux acteurs opérant sur le marché du diagnostic tissulaire sont :

• F. Hoffmann-La Roche SA (Suisse)
• Danaher (États-Unis)
• Thermo Fisher Scientific (États-Unis)
• Abbott (États-Unis)
• Agilent Technologies Inc. (États-Unis)
• Merck KGaA (États-Unis)
• Sakura Finetek Japan Co. Ltd. (États-Unis)
• BD (États-Unis)
• QIAGEN (Allemagne)
• Bio SB (États-Unis)
• BioGenex. (États-Unis)
• Abcam Limited (Royaume-Uni)
• Cell Signaling Technology Inc. (États-Unis)
• Koninklijke Philips NV (Pays-Bas)
• Le Groupe Menarini (Italie)
• Enzo Life Sciences, Inc. (États-Unis)
• Zenalux Biomedical, Inc. (États-Unis)
• 3DHISTECH Ltd. (Hongrie)
• Lunaphore Technologies SA. (Suisse)
• Biocare Medical, LLC. (États-Unis)
• Genomic Health, Inc. (États-Unis)

SKU-28794